A detailed history of Fagan Associates, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Fagan Associates, Inc. holds 26,495 shares of VRTX stock, worth $13.3 Million. This represents 2.23% of its overall portfolio holdings.

Number of Shares
26,495
Previous 25,938 2.15%
Holding current value
$13.3 Million
Previous $10.8 Million 14.54%
% of portfolio
2.23%
Previous 2.06%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$392.81 - $485.53 $218,795 - $270,440
557 Added 2.15%
26,495 $12.4 Million
Q1 2024

May 06, 2024

BUY
$407.69 - $446.08 $202,214 - $221,255
496 Added 1.95%
25,938 $10.8 Million
Q4 2023

Feb 07, 2024

BUY
$343.0 - $410.68 $121,765 - $145,791
355 Added 1.42%
25,442 $10.4 Million
Q3 2023

Oct 31, 2023

BUY
$338.18 - $362.46 $172,471 - $184,854
510 Added 2.08%
25,087 $8.72 Million
Q2 2023

Aug 08, 2023

BUY
$314.42 - $351.91 $136,143 - $152,377
433 Added 1.79%
24,577 $8.65 Million
Q1 2023

May 03, 2023

SELL
$283.23 - $323.1 $27,473 - $31,340
-97 Reduced 0.4%
24,144 $7.61 Million
Q4 2022

Jan 25, 2023

BUY
$285.76 - $321.48 $71,440 - $80,370
250 Added 1.04%
24,241 $0
Q3 2022

Nov 01, 2022

BUY
$273.83 - $305.53 $73,934 - $82,493
270 Added 1.14%
23,991 $6.95 Million
Q2 2022

Aug 03, 2022

SELL
$234.96 - $292.55 $511,742 - $637,173
-2,178 Reduced 8.41%
23,721 $6.68 Million
Q1 2022

May 06, 2022

BUY
$221.42 - $260.97 $549,121 - $647,205
2,480 Added 10.59%
25,899 $6.76 Million
Q4 2021

Feb 08, 2022

BUY
$177.01 - $223.45 $533,154 - $673,031
3,012 Added 14.76%
23,419 $5.14 Million
Q3 2021

Nov 09, 2021

SELL
$181.39 - $202.99 $187,738 - $210,094
-1,035 Reduced 4.83%
20,407 $3.7 Million
Q2 2021

Aug 06, 2021

BUY
$187.49 - $221.1 $591,905 - $698,012
3,157 Added 17.27%
21,442 $4.32 Million
Q1 2021

May 06, 2021

BUY
$207.02 - $241.31 $3.02 Million - $3.52 Million
14,570 Added 392.19%
18,285 $3.93 Million
Q4 2020

Feb 08, 2021

BUY
$207.01 - $276.09 $769,042 - $1.03 Million
3,715 New
3,715 $878,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Fagan Associates, Inc. Portfolio

Follow Fagan Associates, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fagan Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Fagan Associates, Inc. with notifications on news.